Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 217.50p. Over the last year, Hutchmed (china) shares have traded in a share price r
Is HUTCHMED (China) Limited (HCM) a buy, sell, or hold? What is HUTCHMED (China) Limited's stock price today? Is HUTCHMED (China) Limited a publicly traded stock? What is HUTCHMED (China) Limited's stock symbol? What are your HUTCHMED (China) Limited (HCM) stock predictions? What is...
HUTCHMED (China) Ltd 13:HKG Actions Health CarePharmaceuticals and Biotechnology Price (HKD)20.50 Today's Change-0.40 / -1.91% Shares traded1.99m 1 Year change+4.49% Beta1.2321 Data delayed at least 15 minutes, as of Feb 03 2025 08:08 GMT....
HUTCHMED (China) Limited Share forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for HCM in the last 3 months.
HUTCHMED (China) Limited Share Company page Our story Webcasts Trade recap Fundamentals Analysis EquityWhat's this? Price (GBX)218.00 2.83% (6.00)HCMORD USD0.10 Track 1 instrument Open / Last close217.00 / 218.00 High / Low222.00 / 210.00 Bid / Offer218.00 / 220.00...
DateTypeShareholderTitleTransaction TypeShare PriceSharesValue Oct 20, 2023PurchaseDan EldarDerivative/Non-derivative$0.00 PER SHARE1,938$0 Oct 20, 2023PurchasePaul Rutherford CarterDerivative/Non-derivative$0.00 PER SHARE1,647$0 Oct 20, 2023PurchaseTony MokDerivative/Non-derivative$0.00 PER SHARE1,938...
HUTCHMED (China) Limited 2. Name of scheme: Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”) 3. Period of return: From June 29, 2024 to December 28, 2024 4. Balance under scheme from previous return: 2015 HUTCHMED Share Option Scheme: 46...
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme London: Tuesday, April 21, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 20, 2020, in accordance with the new incentive policy outlined in its full ye...
(35% at CER) to US$214mn in FY23, among which sales of fruquintinib in China increased 15% YoY (22% at CER) to US$108mn, maintaining leadership in patient share (47%) in 3L CRC. Fruquintinib recorded US$15mn in sales in the overseas market in 2023 since the launch in Nov....
HUTCHMED (China) Limited (HCM) profitability grade and underlying metrics. Quant Ratings. Charts: gross margin, EBIT, Net Income, EBITDA, ROE, ROA, etc.